NCT01903460View on ClinicalTrials.gov

Safety and Efficacy Study of LUM001 in the Treatment of Cholestatic Liver Disease in Patients With Alagille Syndrome

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

August 31, 2013

Primary Completion Date

February 28, 2015

Study Completion Date

March 31, 2015

Conditions
Alagille Syndrome
Interventions
DRUG

LUM001

DRUG

Placebo

Trial Locations (3)

B4 6NH

Birmingham Children's Hospital, Birmingham

LS9 7TF

Leeds Teaching Hospitals, Leeds

SE5 9RS

Kings College Hospital, London

Sponsors
All Listed Sponsors
lead

Mirum Pharmaceuticals, Inc.

INDUSTRY